How does INIS's PS Ratio compare to its peers?

INIS is expensive based on its Price-To-Sales Ratio (1.3x) compared to the peer average (0.9x).

How does INIS's PS Ratio compare vs other companies in the US Life Sciences Industry?

INIS is good value based on its Price-To-Sales Ratio (1.3x) compared to the US Life Sciences industry average (3.4x).

What is INIS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate INIS's Price-To-Sales Fair Ratio for valuation analysis.

What is the Fair Price of INIS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

INIS ($0.03) is trading below our estimate of [[fair value]] ($0.12)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

INIS Stock Overview

Manufactures and sells nuclear medicine calibration and reference standards, cobalt-60 products, sodium iodide I-131 drug product, and radiochemicals for clinical research and life sciences in the United States and internationally. More details

INIS fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Trading at 71.9% below our estimate of its fair value

Risk Analysis

Earnings have declined by 7.5% per year over past 5 years

Volatile share price over the past 3 months compared to the US market

Does not have a meaningful market cap ($18M)

My Notes

Capture your thoughts, links and company narrative

International Isotopes Inc. Competitors

ImmunoPrecise Antibodies

NasdaqGM:IPA

US$13.4m

Bionano Genomics

NasdaqCM:BNGO

US$19.9m

IsoPlexis

NasdaqGS:ISO

US$30.3m

Pharma-Bio Serv

OTCPK:PBSV

US$12.6m

Price History & Performance

Summary of share price highs, lows and changes for International Isotopes
Historical stock prices
Current Share Price	US$0.034
52 Week High	US$0.054
52 Week Low	US$0.02
Beta	0.50
1 Month Change	-7.69%
3 Month Change	-6.67%
1 Year Change	-32.80%
3 Year Change	-65.00%
5 Year Change	-28.51%
Change since IPO	-99.64%

Recent updates

Shareholder Returns

	INIS	US Life Sciences	US Market
7D	-5.1%	-2.1%	-2.4%
1Y	-32.8%	-5.5%	23.4%

Return vs Industry: INIS underperformed the US Life Sciences industry which returned -5.5% over the past year.

Return vs Market: INIS underperformed the US Market which returned 23.4% over the past year.

Price Volatility

Is INIS's price volatile compared to industry and market?
INIS volatility
INIS Average Weekly Movement	14.3%
Life Sciences Industry Average Movement	9.2%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.8%
10% least volatile stocks in US Market	3.1%

Stable Share Price: INIS's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: INIS's weekly volatility has decreased from 21% to 14% over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
1995	40	Shahe Bagerdjian	www.intisoid.com

International Isotopes Inc. manufactures and sells nuclear medicine calibration and reference standards, cobalt-60 products, sodium iodide I-131 drug product, and radiochemicals for clinical research and life sciences in the United States and internationally. It operates through four segments: Nuclear Medicine Standards, Cobalt Products, Theranostics Products, and Fluorine Products. The Nuclear Medicine Standards segment manufactures sources and standards associated with single photon emission computed and positron emission tomography imaging, patient positioning, and calibration or operational testing of dose measuring equipment for the nuclear pharmacy industry.

International Isotopes Inc. Fundamentals Summary

How do International Isotopes's earnings and revenue compare to its market cap?
INIS fundamental statistics
Market cap	US$17.59m
Earnings (TTM)	-US$346.30k
Revenue (TTM)	US$13.15m

1.3x

P/S Ratio

-50.8x

P/E Ratio

Is INIS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
INIS income statement (TTM)
Revenue	US$13.15m
Cost of Revenue	US$4.85m
Gross Profit	US$8.30m
Other Expenses	US$8.64m
Earnings	-US$346.30k

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.00066
Gross Margin	63.12%
Net Profit Margin	-2.63%
Debt/Equity Ratio	148.3%

How did INIS perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/22 07:31
End of Day Share Price	2024/12/20 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

International Isotopes Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Mauro Suarez	Alliance Global Partners
David Matthew Kratochvil	Alliance Global Partners